Comparison of efficacy and prognostic impact of adjuvant (131)I therapy at 3.7 GBq and 5.55 GBq in DTC patients with unexplained sTg elevation. Sun N, Liu M, Xi C, Luo Q, et al. BMC Cancer 2025;25:912.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sun N, Liu M, Xi C, Luo Q, et al. Comparison of efficacy and prognostic impact of adjuvant (131)I therapy at 3.7 GBq and 5.55 GBq in DTC patients with unexplained sTg elevation. BMC Cancer 2025;25:912.
PMID: 40399817